<DOC>
	<DOC>NCT02885662</DOC>
	<brief_summary>To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.</brief_summary>
	<brief_title>Study of CS-3150 in Patients With Primary Aldosteronism</brief_title>
	<detailed_description />
	<mesh_term>Hyperaldosteronism</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Male and female subjects aged 20 years or older at informed consent Patients diagnosed primary aldosteronism by screening test of plasma aldosterone concentration PAC and aldosterone to renin ratio (ARR), and confirmatory testing Patients satisfying following blood pressure; sitting systolic blood pressure (SBP) ≥ 140 mmHg and &lt;180 mmHg sitting diastolic blood pressure (DBP) ≥ 90 mmHg and &lt;110 mmHg Secondary hypertension except primary aldosteronism or hypertensive emergency Patients diagnosed diabetic nephropathy Patients with type 1 diabetes eGFR &lt; 30 mL/min/1.73m2 Serum potassium level &lt; 3.0 or ≥ 5.1 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Primary aldosteronism</keyword>
	<keyword>Hypertension</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
</DOC>